BioPharma Credit: a risky punt on promising new drugs

BioPharma Credit, a life-sciences investment trust, offers a tempting yield. But the dangers may be high when the credit cycle turns.

Like Hamlet's sorrows, defaults tend to come in battalions

Copyright (c) 2008 Shutterstock. No use without permission.

BioPharma Credit offers a tempting yield, but the dangers may be high when the credit cycle turns

Having raised $762m in its stockmarket debut in early 2017, BioPharma Credit (LSE: BPCR)went on to raise another $154m in December and $164m in April, taking the total to well over $1bn. Admittedly, half of the initial money came from existing investors in a private fund who converted their holdings into listed shares, but that still makes this one of the biggest cash raisings in the investment-funds sector in recent years.

Advertisement - Article continues below

BioPharma Credit, as the name implies, lends money to the life-sciences sector. It invests in "corporate or royalty debt secured by the cash flow derived from the sale of approved life-science products", but up to 35% of the portfolio can be unsecured. The firms it lends to may still be lossmaking and so would struggle to raise conventional debt from banks or investors, but anticipate a significant increase in cash flow, perhaps from new products.

Expensive capital

For the companies that borrow, this is very expensive capital, implying that the loans are risky. Yet Perfall doesn't see this as risky "unless you don't know what you are doing". The managers, Pharmakon Advisors, have invested $2.3bn since 2009 in 30 transactions and have suffered no defaults or re-pricings, he points out. This is encouraging, but these have been good times for credit. As Claudius warns in Hamlet, "when sorrows come, they come not single spies but in battalions". One day, the risk implied by these high returns may be all too apparent.

Advertisement - Article continues below

The loans are for between five and seven years, but BPCR is looking to be repaid early. Proceeds from repayment would then be recycled into new loans, subject to BPCR's continuation votes. Loans are typically for less than half the appraised value of a new product, but the portfolio is concentrated, with up to 30% invested in a single credit.

Of the initial amounts raised, $339m was invested in a seed portfolio of already acquired assets. Further investments have reduced the cash to $149m, but two investments account for nearly half the assets and four for nearly 75%. The largest is the $322m committed to oncology-focused biotechnology company Tesoro. Its main product was approved last year in the US and the EU. If predicted sales figures are achieved, the loan will probably be repaid early. In April, $194m was committed to private pharma firm Sebela the loan appears to have been taken out to fund an acquisition.

Reckless borrowers?

The 7% yield looks attractive, but the dividend outlook isn't certain. Future loans could be at lower returns as easily as higher ones (implying a dividend cut) unless the fund takes on riskier loans. Overall, investors would do well to remain cautious.



Investment trusts

If you think now is a good time to buy, look at these investment trusts

With the latest market slides, an awful lot of assets are beginning to look very cheap indeed. If you are thinking of buying, Merryn Somerset Webb has…
10 Mar 2020

How to build a properly diversified investment trust portfolio

Max King explains how to build a well diversified portfolio using one of our favourite tools – investment trusts.
25 Feb 2020

Why investment trusts are the best vehicle for your money

Max King explains the advantages of investment trusts – sometimes called closed-ended funds – over their open-ended counterparts (or Oeics).
11 Feb 2020

Investment trusts: the Cinderella of investment arrives at the ball

Investors should look beyond the market noise of a single year and examine the bigger picture. Max King explains what we can learn from 25 years of in…
8 Jan 2020

Most Popular

UK Economy

What bounce back loans can tell us about how we’ll pay for all this

The government will guarantee emergency "bounce back loans" for small businesses hit by Covid-19. Inevitably, many businesses will default. And there'…
1 Jun 2020
Global Economy

The MoneyWeek Podcast: James Ferguson on the virus, the lockdown, and what comes next

Merryn talks to MoneyWeek regular James Ferguson of Macrostrategy Partnership about what's happened so far with the virus; whether the lockdown was th…
28 May 2020

As full lockdown ends, what are the risks for investors?

In the UK and elsewhere, people are gradually being let off the leash as the lockdown begins to end. John Stepek looks at what risks remain for invest…
29 May 2020